Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p

Xianjie Chen,Xianjie Chen,Zhenyuan Xu,Zhenyuan Xu,Meng Lu,Meng Lu,Wenjun Ding,Wenjun Ding,Jun Zhong,Jun Zhong,Suihui Deng,Suihui Deng,Siyan Li,Siyan Li,Jifei Miao,Xiaoyi Liu,Xiaoyi Liu,Quan Wen,Sen Ye,Sen Ye,Chun Li,Hui Li,Hui Li

DOI: https://doi.org/10.1016/j.bbrc.2023.03.005

IF: 3.1

2023-05-14

Biochemical and Biophysical Research Communications

Abstract:The abnormal immune response mediated by malignant melanoma is related to PD1. Paeonol has pharmacological antitumor activity. Previous studies have indicated that paeonol induces tumor cell apoptosis, but its underlying mechanism in tumor immunity remains unknown. In this study, malignant melanoma was established in normal and thymectomized mice to determine the important role of the thymus in the antitumor effects of paeonol. Paeonol-treated thymocytes were cocultured with melanoma cell spheres to further evaluate the regulatory role of thymocytes in tumor immune dysfunction. Studies have shown that PD1 may be targeted by miR-139–5p. Our results revealed that tumor-induced thymic atrophy was significantly accompanied by high PD1 expression and low miR-139–5p expression. Interestingly, paeonol significantly reversed thymic atrophy and largely protected thymocytes against low PD1 expression and high miR-139–5p expression. Dual-luciferase assays indicated that miR-139–5p interacted with the 3′ untranslated region (3′-UTR) of PD1. These results showed that paeonol alleviates PD1-mediated antitumor immunity by reducing miR-139–5p expression and demonstrated a novel mechanism for melanoma immunotherapy.

biochemistry & molecular biology,biophysics